firstwordpharmaJune 10, 2021
Tag: Elicera , CAR T-cells , gene therapy
Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that the Company's issue of units of approximately SEK 52 million prior to the planned listing on the Nasdaq First North Growth Market (the "Offer") was subscribed for approximately 171 percent spread over about 3 600 subscribers. Subscriptions have been received from the public as well as from anchor investors who have made subscription commitments. Due to the great demand, the Board has decided to use the over-allotment option of an additional SEK 10 million. In total, the Company will thus receive SEK 62 million before issue costs. The preliminary first trading day for the Company's shares and warrants on Nasdaq First North Growth Market is June 11, 2021 for the shares and around June 30 for the warrants, provided the application receives final approval.
“We are very happy and proud of the great interest that Elicera has generated, and we warmly welcome all new shareholders. The capital injection makes it possible for us to implement our development plan and increase the pace of our various projects. There are significant unmet medical needs in our fast-growing clinical areas, and we look forward to being able to provide vital treatments for cancer patients who in many cases lack adequate treatment alternatives.”
Elicera has completed an issue prior to the planned listing on the Nasdaq First North Growth Market. The public and institutional investors in Sweden and abroad were offered to subscribe for a maximum of 6,500,000 units at a price of SEK 8.00 per unit, which corresponds to issue proceeds of SEK 52 million before issue costs. Each unit consists of one (1) share and one (1) free warrant of series TO1. The subscription period in the Offer lasted during the period May 24 - June 8, 2021. The proceeds from the Offer are intended to be used primarily to finance the development of clinical and preclinical studies of the Company's four drug candidates.
Due to the heavily oversubscribed Offer, all 6,500,000 units are issued, all to be paid in cash. In addition, the Board has decided to, in accordance with the terms described in the prospectus published on May 21, 2021, issue an additional 1,250,000 units through so-called over-allotment, against cash payment. In total, Elicera will thus receive SEK 62 million in cash issue proceeds before issue costs. After the registration of all the above issued units, the number of shares in the Company will increase from 12,032,000 to 19,782,000 and the number of warrants of series TO1 will amount to 7,750,000. The share capital in the Company will increase from SEK 505,344 to SEK 830,844. If all warrants of series TO1 are exercised for subscription of shares during the period 1 November - 30 November 2022, an additional 3,875,000 new shares will be issued and the Company's share capital will thus increase by SEK 162,750. If all warrants of series TO1 are exercised for subscription of shares, the Company will receive approximately SEK 45 million before issue costs. The total dilution effect due to the Offer amounts to approximately 39% (excluding any exercise of the warrants of series TO1).
Approximately 2 330 subscribers have received allotment and will be notified of this via their respective bank. Shares will be delivered in connection with the payment of cash. As soon as the Offer has been registered with the Swedish Companies Registration Office, new warrants of series TO1 will be delivered to the respective depot or VP account. Following the completion of the Offer, the number of shareholders will amount to approximately 2 335.
Preliminary first trading day for the Company's shares on Nasdaq First North Growth Market is on June 11, 2021, subject to final approval of the application. The warrants that are included free of charge in the units that are issued will be admitted to trading after the issue's registration according to a later press release, tentatively on 30 June.
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: